Press
:
Newsroom
:
articles
Press releases
05 SEP 2007 / Product
Actavis Launches Carvedilol Tablets in the United States
Morristown, NJ, September 5, 2007 - Actavis announced today that it has received approval from the U.S. Food & Drug Administration to market Carvedilol tablets in the United States. Distribution of the product will commence immediately.
Carvedilol tablets, the generic equivalent of GlaxoSmithKline's Coreg tablets, will be available in 3.125, 6.25, 12.5, and 25mg strengths. Carvedilol tablets are indicated for the treatment of left ventricular dysfunction following myocardial infarction and for the management of essential hypertension.
Annual sales of Carvedilol tablets in the U.S. were approximately US$1.7 billion for the twelve months ending June 2007 according to IMS Health data.